Q1 Net Profit Grows 60% YoY to ₹1.29 Cr; Revenue Jumps 427% YoY
Worth Investment & Trading Co Ltd reported a significant YoY revenue jump to ₹6.53 Cr in Q1 FY26, up from ₹1.24 Cr in the previous year. Net profit followed suit, rising 60.6% YoY to ₹1.29 Cr, though it remained flat on a QoQ basis compared to March 2026. A critical observation is the massive spike in finance costs to ₹4.54 Cr (from ₹0.04 Cr YoY), indicating a heavily leveraged expansion of the loan book. The company continues to operate with high concentration risk, with the majority of its assets deployed as loans to a single sister concern.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company has significantly scaled its lending operations compared to a year ago, resulting in higher interest income but also a massive increase in borrowing costs.
ஏன் இது முக்கியம்The sharp rise in finance costs and flat QoQ profit suggest that while the company is growing its top line, the margins are being squeezed by the cost of capital required to fund its concentrated loan book.
Revenue (Q1 FY26): ₹6.53 கோடிNet Profit (Q1 FY26): ₹1.29 கோடிFinance Costs: ₹4.54 கோடிRevenue vs TTM Revenue: ~50.2%YoY Revenue Growth: 427.6%
📅 குறுகிய காலம்The market may focus on the strong YoY growth figures, but the high interest burden and flat QoQ performance are likely to limit any significant upside.
📈 நீண்ட காலம்The company's structural dependence on a single group entity for 94% of its loan book remains a major long-term risk factor, regardless of quarterly growth.
⚠ அபாய எச்சரிக்கைகள்
- Extreme counterparty concentration (Aarey Drugs)
- High leverage (Debt/Equity of 6.64)
- Sharp increase in finance costs
👀 கவனிக்க வேண்டியவை
Investors should closely monitor the creditworthiness of Aarey Drugs and Pharmaceuticals, as the company's revenue is almost entirely dependent on this single borrower. Watch for any stabilization in finance costs, which are currently consuming a large portion of operating income.
